Search

Search results

49 results found

Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAFV600E Papillary Thyroid Carcinoma.

Valvo, Veronica, Asumi Iesato, Taylor R Kavanagh, Carmen Priolo, Zsuzsanna Zsengeller, Alfredo Pontecorvi, Isaac E Stillman, Suzanne D Burke, Xiaowen Liu, and Carmelo Nucera. 2021. “Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAFV600E Papillary Thyroid Carcinoma.”. Thyroid : Official Journal of the American Thyroid Association 31 (9): 1335-58.

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.

Antonello, Zeus A, Nancy Hsu, Manoj Bhasin, Giovanni Roti, Mukta Joshi, Paul Van Hummelen, Emily Ye, et al. 2017. “Vemurafenib-Resistance via de Novo RBM Genes Mutations and Chromosome 5 Aberrations Is Overcome by Combined Therapy With Palbociclib in Thyroid Carcinoma With BRAFV600E.”. Oncotarget 8 (49): 84743-60.